Exenatide in adolescent patients with type 2 diabetes: Pharmacokinetics, pharmacodynamics, safety, and

被引：0
|
作者：
Malloy, Jaret
Guan, Xuesong
Kothare, Prajakti.
Capparelli, Edmund
Fineman, Mark
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A145 / A145
页数：1
相关论文
共 50 条
  • [21] A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
    Barrientos-Perez, Margarita
    Hsia, Daniel S.
    Sloan, Lance
    Nell, Haylene
    Mungur, Ounisha
    Hovsepian, Lionel
    Schmider, Wolfgang
    Spranger, Robert
    Yang, Na
    Niemoeller, Elisabeth
    PEDIATRIC DIABETES, 2022, 23 (06) : 641 - 648
  • [22] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Heise, Tim
    Seman, Leo
    Macha, Sreeraj
    Jones, Peter
    Marquart, Alexandra
    Pinnetti, Sabine
    Woerle, Hans J.
    Dugi, Klaus
    DIABETES THERAPY, 2013, 4 (02) : 331 - 345
  • [23] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Tim Heise
    Leo Seman
    Sreeraj Macha
    Peter Jones
    Alexandra Marquart
    Sabine Pinnetti
    Hans J. Woerle
    Klaus Dugi
    Diabetes Therapy, 2013, 4 : 331 - 345
  • [24] Safety, pharmacokinetics, and pharmacodynamics of a single subcutaneous dose of VRS-859 in patients with type 2 diabetes
    Cleland, J.
    Aronson, R.
    Humphriss, E.
    Shore, C. R.
    Bright, G.
    Zhou, R.
    Kipnes, M. S.
    DIABETOLOGIA, 2012, 55 : S338 - S339
  • [25] Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of VRS-859 in Patients With Type 2 Diabetes
    Cleland, Jeffrey L.
    Aronson, Ronnie
    Humphriss, Eric
    Shore, Camille
    Zhou, Rong
    Kipnes, Mark S.
    DIABETES, 2012, 61 : A285 - A285
  • [26] Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
    Retlich, Silke
    Duval, Vincent
    Graefe-Mody, Ulrike
    Friedrich, Christian
    Patel, Sanjay
    Jaehde, Ulrich
    Staab, Alexander
    CLINICAL PHARMACOKINETICS, 2015, 54 (07) : 737 - 750
  • [27] Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
    Silke Retlich
    Vincent Duval
    Ulrike Graefe-Mody
    Christian Friedrich
    Sanjay Patel
    Ulrich Jaehde
    Alexander Staab
    Clinical Pharmacokinetics, 2015, 54 : 737 - 750
  • [28] The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
    Heimburger, Sebastian M.
    Bronden, Andreas
    Johansen, Nicklas J.
    Dejgaard, Thomas F.
    Vilsboll, Tina
    Knop, Filip K.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (05) : 501 - 510
  • [29] The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension
    Linnebjerg, H.
    Kothare, P.
    Park, S.
    Mace, K.
    Mitchell, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (11) : 651 - 658
  • [30] Liraglutide trial in paediatric subjects with type 2 diabetes: safety, tolerability and pharmacokinetics/pharmacodynamics
    Battelino, T.
    Klein, D.
    Chatterjee, D. J.
    Hale, P.
    Chang, C. T.
    Arslanian, S.
    DIABETOLOGIA, 2012, 55 : S7 - S7
12345